New insider activity at InspireMD ( (NSPR) ) has taken place on May 21, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
In a recent insider transaction at InspireMD, Chief Commercial Officer Shane Thomas Gleason sold 85,295 shares of the company’s stock, with the total sale valued at $189,594. This move highlights notable executive-level activity in InspireMD’s shares, which investors may watch closely as they assess insider sentiment and trading patterns around the company.
Recent Updates on NSPR stock
InspireMD shares reacted to Q1 results that showed revenue more than doubling on strong U.S. and international demand, but sentiment was tempered by a voluntary U.S. recall of the CGuard Prime 135 cm delivery system and withdrawal of 2026 revenue guidance. Analysts trimmed price targets mainly to reflect the temporary halt in U.S. commercial activity, lower near-term revenue visibility, and added recall-related costs, while still citing manageable technical fixes and intact long-term stent potential.
Spark’s Take on NSPR Stock
According to Spark, TipRanks’ AI Analyst, NSPR is a Neutral.
The score is held down primarily by very weak profitability and heavy cash burn despite improving revenue and gross margin. Technicals also reflect a persistent downtrend. Earnings-call fundamentals are mixed: strong growth and regulatory progress are outweighed in the near term by the U.S. commercial pause/recall, withdrawn guidance, higher expenses, and declining cash; valuation provides limited support with a very high P/E.
To see Spark’s full report on NSPR stock, click here.
More about InspireMD
YTD Price Performance: -43.82%
Average Trading Volume: 267,533
Technical Sentiment Signal: Sell
Current Market Cap: $46.84M